Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Integrating IoT for Soil Monitoring and Hybrid Machine Learning in Predicting Tomato Crop Disease in a Typical South India Station.Sensors (Basel, Switzerland) · 2024
   Article
2. Local modalities for inoperable hepatocellular carcinoma: radiofrequency ablation versus stereotactic body radiotherapy.Annals of translational medicine · 2018
   Article

Corrections and comments

• Comment on
  Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.2018
• Comment on
  Comparing Modalities Using the National Cancer Database: Concerns With Rajyaguru et al.2018
• Comment on
  Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data.2018
• Comment on
  Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database.2018
• Comment on
  Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma?2018
• Comment on
  What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma?2018
• Comment on
  Correspondence on Rajyaguru et al.2018
• Comment on
  Survival Analyses Are Flawed When Neglecting Barcelona Clinic Liver Cancer Staging.2018
• Comment on
  Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma?2018
• Comment on
  Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: Caution When Interpreting Observational Data.2018
• Comment on
  Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial?2018
• Comment on
  Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma: Does Radiation Dose Make a Difference?2018

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as